Kestra Advisory Services, LLC Cognition Therapeutics Inc Transaction History

Kestra Advisory Services, LLC

  • $19.6 Billion
  • Q1 2025

A detailed history of Kestra Advisory Services, LLC transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Kestra Advisory Services, LLC holds 177,434 shares of CGTX stock, worth $56,778. This represents 0.0% of its overall portfolio holdings.

Number of Shares
177,434
Previous 177,434 -0.0%
Holding current value
$56,778
Previous $133,000 44.36%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 10, 2025
SELL
$0.38 - $0.84 $4,180 - $9,240
-11,000 Reduced 5.84%
177,434 $133,000
Q2 2024

Aug 14, 2024
SELL
$1.66 - $2.62 $18,260 - $28,820
-11,000 Reduced 5.52%
188,434 $312,000
Q1 2024

May 15, 2024
SELL
$1.78 - $2.53 $35,600 - $50,599
-20,000 Reduced 9.11%
199,434 $362,000
Q4 2023

Feb 14, 2024
BUY
$0.96 - $2.42 $39,024 - $98,373
40,650 Added 22.74%
219,434 $405,000
Q3 2023

Nov 09, 2023
BUY
$1.25 - $1.9 $6,250 - $9,500
5,000 Added 2.88%
178,784 $257,000
Q2 2023

Aug 11, 2023
BUY
$1.56 - $3.38 $122,903 - $266,289
78,784 Added 82.93%
173,784 $318,000
Q1 2023

May 12, 2023
BUY
$1.51 - $2.3 $67,016 - $102,078
44,382 Added 87.68%
95,000 $188,000
Q4 2022

Jan 31, 2023
BUY
$1.17 - $3.51 $41,673 - $125,019
35,618 Added 237.45%
50,618 $106,000
Q2 2022

Aug 12, 2022
SELL
$1.5 - $3.45 $335,499 - $771,647
-223,666 Reduced 93.72%
15,000 $32,000
Q1 2022

Apr 26, 2022
BUY
$2.41 - $6.9 $345,965 - $990,522
143,554 Added 150.93%
238,666 $656,000
Q4 2021

Jan 20, 2022
BUY
$5.1 - $12.98 $485,071 - $1.23 Million
95,112 New
95,112 $601,000

Others Institutions Holding CGTX

# of Institutions
58
Shares Held
14M
Call Options Held
0
Put Options Held
0
View Full List

About COGNITION THERAPEUTICS INC

CGTX Quotes by TradingView
  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $7.27M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Kestra Advisory Services, LLC Portfolio

Follow Kestra Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kestra Advisory Services, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email